Hansa Biopharma AB
F:24H
Hansa Biopharma AB
F:24H
Price:
2.502
EUR
2.04%
Market Cap:
€169.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
H
|
Hansa Biopharma AB
F:24H
|
SE |
|
V
|
Veeva Systems Inc
LSE:0LO3
|
US |
|
M
|
Magna International Inc
XMUN:MGA
|
CA |
|
Q
|
Qorvo Inc
F:2QO
|
US |
|
F
|
Fifth Third Bancorp
DUS:FFH
|
US |
|
O
|
Occidental Petroleum Corp
XMUN:OPC
|
US |
|
H
|
Hasbro Inc
DUS:HAS
|
US |
|
E
|
electroCore, Inc.
F:43E
|
US |
|
S
|
Somboon Advance Technology PCL
SET:SAT
|
TH |
|
V
|
Volkswagen AG
XMUN:VOW
|
DE |
|
S
|
Sumitomo Corp
XMUN:SUMA
|
JP |
|
C
|
Crown Castle International Corp
F:8CW
|
US |
|
Sanofi SA
OTC:SNYNF
|
FR |
|
S
|
Siltronic AG
DUS:WAF
|
DE |
|
S
|
Sarepta Therapeutics Inc
XMUN:AB3A
|
US |
|
F
|
Federal National Mortgage Association
XBER:FNM
|
US |
|
M
|
Morgan Stanley
XHAM:DWD
|
US |
|
J
|
Just Eat Takeaway.com NV
XMUN:T5W
|
NL |
Wall St Price Targets
24H Price Targets Summary
Hansa Biopharma AB
Hansa Biopharma AB
Wall Street analysts forecast 24H stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for 24H is 8.586 EUR with a low forecast of 3.974 EUR and a high forecast of 12.159 EUR.
Lowest Forecast
Price Target
3.974
EUR
59% Upside
Average Forecast
Price Target
8.586
EUR
243% Upside
Highest Forecast
Price Target
12.159
EUR
386% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 24H's stock price target?
Price Target
8.586
EUR
8.586
EUR
According to Wall Street analysts, the average 1-year price target for 24H is 8.586 EUR with a low forecast of 3.974 EUR and a high forecast of 12.159 EUR.
What is the Revenue forecast for Hansa Biopharma AB?
Projected CAGR
51%
51%
Over the last 13 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 8 years is 51%.
